Company / SG&A Expense
CytomX Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$29.8M
FY2025
5-year range
$29.7M / $42.8M
FY2021-FY2025
Trend
+0.4%
vs FY2024
Sector context
#185 of 213
Health Care
What the data says
CytomX Therapeutics, Inc.'s sg&a expense of $30M is lower than 87% of companies in the Health Care sector (FY2025). SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $30M.
Based on SEC 10-K filings.
$30M in FY2025 with a 5-year CAGR of -3.7%.
Remained stable around $30M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -11.4%
- 5-Year CAGR
- -3.7%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 213This company $29.8M Sector average $722.3M
▼
-95.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.7%, indicating a declining trend.
- In FY2025, sg&a expense increased 0.4% year-over-year.
- Ranks #185 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.8M | +0.4% |
| FY2024 | $29.7M | -1.0% |
| FY2023 | $30.0M | -29.9% |
| FY2022 | $42.8M | +9.4% |
| FY2021 | $39.2M | +8.7% |
| FY2020 | $36.0M | -2.0% |
| FY2019 | $36.8M | +9.7% |
| FY2018 | $33.5M | +30.9% |
| FY2017 | $25.6M | +28.8% |
| FY2016 | $19.9M | +301.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026